Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Jean-Claude

Showing results (11-20 of 76) with videos related to

Pageof 8
Sort By:
Bioorganic & Medicinal Chemistry Letters|December 23, 2016
Design, synthesis and biological activity of novel molecules designed to target PARP and DNAElliot Goodfellow, Zhor Senhaji Mouhri, Christopher Williams, et al.
Drug Metabolism Letters|April 5, 2011
In vitro and in vivo biodistribution of ZRS1, a stabilized type I N-acetoxymethyl carbamate-containing combi-moleculeNahid Golabi, Zakaria Rachid, Qiyu Qiu, et al.
Bioorganic & Medicinal Chemistry Letters|October 31, 2000
Design and synthesis of a novel water soluble benzotetrazepinoneB Dumont-Hornebeck, Y N Strube, D Vasilescu, et al.
Leukemia Research|March 10, 2005
Cytokinetics and mechanism of action of AKO4: a novel nitrogen mustard targeted to bcr-ablAthanasia Katsoulas, Zakaria Rachid, Fouad Brahimi, et al.
Journal of Medicinal Chemistry|September 19, 2003
The combi-targeting concept: chemical dissection of the dual targeting properties of a series of "combi-triazenes"Zakaria Rachid, Fouad Brahimi, Athanasia Katsoulas, et al.
Leukemia Research|May 3, 2005
Engineering 3-alkyltriazenes to block bcr-abl kinase: a novel strategy for the therapy of advanced bcr-abl expressing leukemiasAthanasia Katsoulas, Zakaria Rachid, Fouad Brahimi, et al.
Anti-Cancer Drugs|January 24, 2006
The combi-targeting concept: evidence for the formation of a novel inhibitor in vivoNuria Merayo, Zakaria Rachid, Qiyu Qiu, et al.
Journal of Medicinal Chemistry|June 3, 2020
Design and Synthesis of a Trifunctional Molecular System "Programmed" to Block Epidermal Growth Factor Receptor Tyrosine Kinase, Induce High Levels of DNA Damage, and Inhibit the DNA Repair Enzyme (Poly(ADP-ribose) Polymerase) in Prostate Cancer CellsJulie Schmitt, Shanlong Huang, Elliot Goodfellow, et al.
Investigational New Drugs|July 11, 2020
Subcellular distribution and mechanism of action of AL906, a novel and potent EGFR inhibitor rationally designed to be green fluorescentNahid Golabi, Anne-Laure Larroque, Lisa Peyrard, et al.
Investigational New Drugs|August 21, 2013
ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activityMaria Ait-Tihyaty, Zakaria Rachid, Anne-Laure Larroque-Lombard, et al.
Pageof 8

Showing results (11-20 of 76) with videos related to

Sort By:
Pageof 8
Bioorganic & Medicinal Chemistry Letters|December 23, 2016
Design, synthesis and biological activity of novel molecules designed to target PARP and DNAElliot Goodfellow, Zhor Senhaji Mouhri, Christopher Williams, et al.
Drug Metabolism Letters|April 5, 2011
In vitro and in vivo biodistribution of ZRS1, a stabilized type I N-acetoxymethyl carbamate-containing combi-moleculeNahid Golabi, Zakaria Rachid, Qiyu Qiu, et al.
Bioorganic & Medicinal Chemistry Letters|October 31, 2000
Design and synthesis of a novel water soluble benzotetrazepinoneB Dumont-Hornebeck, Y N Strube, D Vasilescu, et al.
Leukemia Research|March 10, 2005
Cytokinetics and mechanism of action of AKO4: a novel nitrogen mustard targeted to bcr-ablAthanasia Katsoulas, Zakaria Rachid, Fouad Brahimi, et al.
Journal of Medicinal Chemistry|September 19, 2003
The combi-targeting concept: chemical dissection of the dual targeting properties of a series of "combi-triazenes"Zakaria Rachid, Fouad Brahimi, Athanasia Katsoulas, et al.
Leukemia Research|May 3, 2005
Engineering 3-alkyltriazenes to block bcr-abl kinase: a novel strategy for the therapy of advanced bcr-abl expressing leukemiasAthanasia Katsoulas, Zakaria Rachid, Fouad Brahimi, et al.
Anti-Cancer Drugs|January 24, 2006
The combi-targeting concept: evidence for the formation of a novel inhibitor in vivoNuria Merayo, Zakaria Rachid, Qiyu Qiu, et al.
Journal of Medicinal Chemistry|June 3, 2020
Design and Synthesis of a Trifunctional Molecular System "Programmed" to Block Epidermal Growth Factor Receptor Tyrosine Kinase, Induce High Levels of DNA Damage, and Inhibit the DNA Repair Enzyme (Poly(ADP-ribose) Polymerase) in Prostate Cancer CellsJulie Schmitt, Shanlong Huang, Elliot Goodfellow, et al.
Investigational New Drugs|July 11, 2020
Subcellular distribution and mechanism of action of AL906, a novel and potent EGFR inhibitor rationally designed to be green fluorescentNahid Golabi, Anne-Laure Larroque, Lisa Peyrard, et al.
Investigational New Drugs|August 21, 2013
ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activityMaria Ait-Tihyaty, Zakaria Rachid, Anne-Laure Larroque-Lombard, et al.
Pageof 8